
    
      This study is conducted in Chinese patients with advanced refractory metastatic solid tumors.
      A total of 8-10 mL of blood will be collected from eligible patients and used for extracting
      circulating tumor DNA. Blood-MSI status will be tested based on SPANOM technique developed by
      3D Medicines Inc. Shanghai, China. Patients are encouraged to provide tissues collected from
      progressive disease for tissue-MSI testing (not required for inclusion).
    
  